Acute myeloid leukemia (AML) is a hematologic malignancy that is not completely cured in patients even after heavy chemotherapy treatments, resulting in the relapses of disease. Inactivation of immune cells such as natural killer (NK) cells is probably one of the causes of relapse. In this review, we described the role of NK cells in AML patients and outlined the current approaches to use of these cells in treatment of AML disease. Relevant articles from 1997 up to date, published in PubMed, were studied and compiled. The articles all contained the keywords: natural killer cell, acute myeloid leukemia, and treatment. Recognition of AML blast cells by NK inhibitory receptors and their interaction reduces NK cell cytotoxicity. On the other hand, NK cell immunotherapy along with administration of cytokines such as IL-2 and IL-15 can enhance the expression of activating receptors such as NKG2D and reduce the incidence of relapse in AML patients. Targeting NK inhibitory receptors and the use of IL-2 and IL-15 cytokine therapy can upregulate NK-activating receptors which decrease the relapse rate and improve the survival of patients with AML.
Journal of Hematopathology – Springer Journals
Published: Oct 11, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud